Interferon-beta response in multiple sclerosis associated with pre-treatment disability;Respuesta al interferón beta en la esclerosis múltiple asociada con la discapacidad previa al tratamiento

Revista de Neurologia

Volumn 43, Issue 6, 2006, Pages 322-329

  Fernández Fernández, Óscar ^a   Fernandez Sanchez V E ^a   Mayorga, C ^a   Guerrero Fernandez M ^b   Leon A ^a   Tamayo Toledo, J A ^a   Alonso, A ^a   Romero, F ^a   Leyva, L ^a   Luque, G ^a   De Ramon E ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

Interferon beta; Multiple sclerosis; Neutralizing antibodies; Response; Treatment

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; NEUTRALIZING ANTIBODY; BIOLOGICAL RESPONSE MODIFIER;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTIPLE SCLEROSIS; RELAPSE; SAMPLE SIZE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADOLESCENT; CHILD; DISABILITY; DISEASE COURSE; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; REGRESSION ANALYSIS;

ADOLESCENT; ADULT; BIOLOGICAL RESPONSE MODIFIERS; CHILD; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON-BETA; MIDDLE AGED; MULTIPLE SCLEROSIS; REGRESSION ANALYSIS;

EID: 35348826811     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4306.2005807     Document Type: Article

References (28)

1. Goodin DS, Frohman EM, Garmany GP Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-78.
2. Durelli L, Oggero A, Verdun E Isoardo G, Ricci A, Barbero P, et al. Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients? J Neurol Sci 2000; 178: 37-41.
3. Cohen JA, Carter JL, Kinkel RP, Schwid SR. Therapy of relapsing multiple sclerosis. Treatment approaches for non-responders. J Neuroimmunol 1999; 98: 29-36.
4. Fernández O, Fernández V, Mayorga C, Guerrero M, León A, Tamayo JA, et al. HLA class II and response to interferon-beta in multiple sclerosis. Acta Neurol Scand 2005; 112: 391-4.
5. Pachner AR, ed. Anti-IFNB antibodies in IFNB-treated MS patients. Neurology 2003; 61 (Suppl 5).
6. PRISMS Study Group. Prevention on relapses and disability by interferon B-1a subcutaneously in multiple sclerosis. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
7. PRISMS Study Group. PRISMS-4: long-term efficacy of interferon-B-1a in relapsing MS. Neurology 2001; 56: 1628-36.
8. Li DK, Zhao GJ, Paty DW; University of British Columbia MS/MRI Analysis Research Group. The SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. MRI results. Neurology 2001; 56: 1505-13.
9. Rudick RA, Simonian JA, Alam JA, Campion M, Scaramucci JO, Jones W, et al. Incidence and significance of neutralising antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998; 50: 1266-72.
10. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralising antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-94.
11. Sorensen PS, Ross C, Clemmesen KM, Frederiksen JL, Jensen K, Kristensen O, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-91.
12. Fernández O, Mayorga C, Luque G, Guerrero M, Guerrero R, Leyva L, et al. Study of binding and neutralising antibodies to IFNB in two groups of relapsing-remitting multiple sclerosis patients treated with IFNB-1a and IFNB-1b. J Neurol 2001; 248: 383-8.
13. Fierlbeck G, Schreiner T. Incidence and clinical significance of therapy-induced neutralizing antibodies against interferon-B. J Interferon Res 1994; 14: 205-6.
14. Antonelli G, Bagnato F, Pozzilli C, Simeoni E, Bastianelli S, Currenti M, et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-B1a. J Interferon Cytokine Res 1998; 18: 345-50.
15. Mayorga C, Luque G, Romero F, Guerrero R, Blanca M, Fernández O. Antibodies to commercially available interferon-beta molecules in multiple sclerosis patients treated with natural interferon-beta. Int Arch Allergy Immunol 1999; 118: 368-71.
16. Arbizu T, Álvarez-Cermeño JC, Decap G, Fernández O, Uría DF, García-Merino A, et al. Interferon beta1-b treatment in patients with relapsing-remitting multiple sclerosis under a standarized protocol in Spain. Acta Neurol Scand 2000; 102: 209-17.
17. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
18. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 906-11.
19. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale. Neurology 1983; 33: 1444-52.
20. Villoslada P, Barcellos LF, Río J, Begovich AB, Tintoré M, Sastre-Garriga J, et al. The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta. J Neuroimmunol 2002; 130: 194-201.
21. Baranzini SE, Mousavi P, Río J, Caillier SJ, Stillman A, Villoslada P, et al. Transcription-based prediction of response to IFNbeta using supervised computational methods PLoS Biol 2005; 3: e2.
22. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. Brain 1989; 112: 133-46.
23. Fernández O, Fernández VE, Guerrero M. Esclerosis múltiple. Madrid: McGraw-Hill-Interamericana; 2003. p. 36-7.
24. Giovannoni, G. Optimising MS disease-modifying therapies: antibodies in perspective. J Neurol 2004; 251: v30-5.
25. Waubant E,Vukusic S, Gignoux L, Durand-Dubief F, Achiti I, Blanc S, et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003; 61: 184-9.
26. Cohen BA, Khan O, Jeffery DR, Bashir K, Rizvi SA, Fox EJ, et al. Identifying and treating patients with suboptimal responses. Neurology 2004; 63 (Suppl 6): S33-40.
27. Freedman MS, Patry DG, Grand'Maison F, Myles ML, Paty DW, Selchen DH, et al. Treatment optimisation in multiple sclerosis. Can J Neurol Sci 2004; 31: 157-68.
28. Comi G. Why to treat early multiple sclerosis patients? Curr Opin Neurol 2000; 13: 235-40.